Together, Teladoc and Livongo will offer select Florida Blue members living with diabetes an end-to-end virtual care experience including connected devices, advanced data science, and telehealth all via the Onlife Health platform. By integrating Teladocs best-in-class virtual care platform with Livongos highly sophisticated capabilities to aggregate data and provide useful insights to members in real time, the combined
entity will provide health consumers a single access point for whole-person care regardless of clinical situation, driving better health outcomes and lower costs.
Livongo is proud to partner with Florida Blue to provide our proven chronic condition management solution to Florida Blue members, said Glen
Tullman, Livongo Founder and Executive Chairman. By leveraging our reseller agreement with Teladoc Health, we were able to accelerate the collaboration, and offer our services to people in a critical moment when caring for our vulnerable
populations is of the utmost importance. This innovative relationship is a great example of how we can combine technology with the empathy so critical to a great health and care experience that meets people where they are and wherever they
are.
As of August 5, 2020, Livongo has more than 1,300 clients, including more than 30 percent of Fortune 500 companies, four of the top
seven health plans, health systems, government organizations, and labor unions.
Cautionary Note Regarding Forward-Looking Statements
This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements regarding the potential transaction between Teladoc
Health, Inc. (Teladoc) and Livongo Health, Inc. (Livongo), including any statements regarding the expected timetable for completing the potential transaction, the ability to complete the potential transaction, the expected
benefits of the potential transaction (including anticipated synergies, projected financial information and future opportunities) and any other statements regarding Teladocs and Livongos future expectations, beliefs, plans, objectives,
results of operations, financial condition and cash flows, or future events or performance. These statements are often, but not always, made through the use of words or phrases such as anticipate, intend, plan,
believe, project, estimate, expect, may, should, will and similar expressions. All such forward-looking statements are based on current expectations of
Teladocs and Livongos management and therefore involve estimates and assumptions that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the results expressed in the
statements. Key factors that could cause actual results to differ materially from those projected in the forward-looking statements include the ability to obtain the requisite Teladoc and Livongo stockholder approvals; uncertainties as to the timing
to consummate the potential transaction; the risk that a condition to closing the potential transaction may not be satisfied; the risk that the anticipated U.S. federal income tax treatment of the transaction is not obtained; litigation relating to
the potential transaction that have been or could be instituted against Teladoc, Livongo or their respective directors; the effects of disruption to Teladocs or Livongos respective businesses; restrictions during the pendency of the
potential transaction that may impact Teladocs or Livongos ability to pursue certain business opportunities or strategic transactions; the effect of this communication on Teladocs or Livongos stock